Jyong Biotech Ltd (MENS)

Jul 28, 2026

Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business

Jul 28, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Income Statement - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Jul 27, 2026

Jul 27, 2026

MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Jul 27, 2026

Jul 27, 2026

Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey

Jul 27, 2026

Jul 26, 2026

Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 26, 2026

Jul 23, 2026

Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria

Jul 23, 2026

Jul 23, 2026

Jyong Biotech targets $22B global BPH market wi... - Pluang

Jul 23, 2026

Jul 23, 2026

Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com

Jul 23, 2026

Jul 23, 2026

Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative

Jul 23, 2026

Jul 23, 2026

Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan

Jul 23, 2026

Jul 22, 2026

Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceHead and Shoulders - dars.gov.et

Jul 22, 2026

Jul 17, 2026

Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat

Jul 17, 2026

Jul 17, 2026

Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16Bollinger Squeeze - dars.gov.et

Jul 17, 2026

Jul 03, 2026

Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business

Jul 03, 2026

Jul 02, 2026

Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria

Jul 02, 2026

Jul 02, 2026

Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com

Jul 02, 2026

Jul 02, 2026

Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang

Jul 02, 2026

Jun 30, 2026

Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et

Jun 30, 2026

Jun 26, 2026

Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView

Jun 26, 2026

Jun 26, 2026

Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView

Jun 26, 2026

Jun 26, 2026

Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView

Jun 26, 2026

Jun 26, 2026

Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView

Jun 26, 2026

Jun 22, 2026

Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber

Jun 22, 2026

Jun 17, 2026

Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey

Jun 17, 2026

Jun 17, 2026

Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView

Jun 17, 2026

Jun 16, 2026

Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey

Jun 16, 2026

Jun 15, 2026

Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com

Jun 15, 2026

Jun 05, 2026

JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill

Jun 05, 2026

May 31, 2026

Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co

May 31, 2026

May 29, 2026

Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang

May 29, 2026

May 27, 2026

Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate

May 27, 2026

May 27, 2026

MENSJyong Biotech Ltd Stock Price and Quote - Finviz

May 27, 2026

May 26, 2026

Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceEarnings Quality Factor - dars.gov.et

May 26, 2026

May 25, 2026

Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate

May 25, 2026

May 25, 2026

Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate

May 25, 2026

May 23, 2026

Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser

May 23, 2026

May 22, 2026

Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser

May 22, 2026

May 21, 2026

MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill

May 21, 2026

May 18, 2026

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com

May 18, 2026

May 15, 2026

Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan

May 15, 2026

May 15, 2026

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative

May 15, 2026

May 15, 2026

DXS INTERNATIONAL PLC (AQSE: DXSP): Issue of New Shares and Notification of Director / PDMR Dealings - Weekly Voice

May 15, 2026